Weil Company’s Avanos Medical AVNS Stock Holding History

Weil Company’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-104	Closed	-$4K	–	129
2019 Q3	$4K	Buy	+104	New	+$3.97K	﹤0.01%	346

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Weil Company's AVNS Position: Q4 2019 in Review

Weil Company sold out of Avanos Medical (AVNS) in Q4 2019, closing a stake of 104 shares — an estimated $4K sold.

Weil Company first reported a position in AVNS in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 293 funds tracked by Wall St. Rank hold AVNS as of Q4 2019.

Weil Company reported no remaining Avanos Medical position as of Q4 2019 after selling out during the quarter.
Weil Company sold 104 Avanos Medical shares in Q4 2019, an estimated $4K.
Weil Company first reported a position in Avanos Medical in Q3 2019 and held it in 1 quarter.
Weil Company's Avanos Medical position peaked at $4K in Q3 2019.
293 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.